|
|
News Breaks | | | | January 10, 2013 | | 18:38 EDT |  | NVS | Novartis drug Afinitor shows benefit in Phase III trial data
Data published today in The Lancet showed that patients on Afinitor tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex experienced a significant reduction in tumor size and the absence of tumor progression. Additionally, a recent issue of The Lancet featured results from a separate everolimus trial demonstrating a reduction in the size of non-cancerous brain tumors known as subependymal giant cell astrocytomas associated with tuberous sclerosis complex. The Phase III EXIST-2 trial published in The Lancet reported that 42% of patients taking everolimus experienced an angiomyolipoma response versus 0% of patients in the placebo arm. Everolimus also demonstrated superiority to placebo for both secondary endpoints assessed. Results from a separate Phase III trial of TSC patients called EXIST-1, also published in a recent issue of The Lancet, showed that 35% of patients with SEGAs associated with TSC treated with everolimus experienced a 50% or greater reduction in SEGA volume versus 0% of patients on placebo. | |
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 20, 2013 | | 07:29 EDT |  | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. | | | May 17, 2013 | | 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information | | | May 16, 2013 | | 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information | | | May 15, 2013 | | 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information | | | May 10, 2013 | | 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information | | | May 6, 2013 | | 16:23 EDT | | NVS | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. | |
|
|
|
|
|
|
